393 related articles for article (PubMed ID: 9504938)
1. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
2. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.
Vanourková Z; Kramer HJ; Erbanová M; Bäcker A; Cervenka L; Husková Z; Chábová VC; Tesar V; Dvorák P; Malý J; Vanecková I
Vascul Pharmacol; 2009; 50(5-6):194-9. PubMed ID: 19563737
[TBL] [Abstract][Full Text] [Related]
5. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
[TBL] [Abstract][Full Text] [Related]
6. Does blockade of the renin angiotensin system affect sympathetic and blood pressure responses to amlodipine in young hypertensive patients?
Ruzicka M; Coletta E; Leenen FH
Am J Hypertens; 2007 Nov; 20(11):1202-8. PubMed ID: 17954368
[TBL] [Abstract][Full Text] [Related]
7. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
8. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
9. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
[TBL] [Abstract][Full Text] [Related]
10. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
Hagino T; Abe K; Tsunoda K; Yoshinaga K
Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
[TBL] [Abstract][Full Text] [Related]
11. Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat.
Champion HC; Estrada LS; Estrada LN; Filep JG; Kadowitz PJ
Can J Physiol Pharmacol; 1998 Feb; 76(2):141-7. PubMed ID: 9635152
[TBL] [Abstract][Full Text] [Related]
12. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats.
Dvorák P; Kramer HJ; Bäcker A; Malý J; Kopkan L; Vanecková I; Vernerová Z; Opocenský M; Tesar V; Bader M; Ganten D; Janda J; Cervenka L
Kidney Blood Press Res; 2004; 27(4):248-58. PubMed ID: 15286437
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
14. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
15. Role of the renin-angiotensin system in hypertension in the elderly.
Nagano M; Higaki J; Mikami H; Ogihara T
Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-1 receptor blockade induces upregulation of renin-angiotensin-aldosterone system expression in terms of blood pressure regulation.
Bo Yang ; Chen YD; Li TD; Feng QZ
J Renin Angiotensin Aldosterone Syst; 2010 Jun; 11(2):119-23. PubMed ID: 20093323
[TBL] [Abstract][Full Text] [Related]
18. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
19. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat.
Ficai S; Herizi A; Mimran A; Jover B
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1100-3. PubMed ID: 11903325
[TBL] [Abstract][Full Text] [Related]
20. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
